STAT+: Novartis gets multiple sclerosis win with BTK inhibitor

STAT+: Pharmalittle: We’re reading about Novartis and Bristol pausing cell therapy trials, a $480K cancer drug, and more

Novartis and Bristol Myers Squibb have paused multiple cell therapy trials, while $480,000 has now become a routine price for a cancer drug.Read the latest pharma headlines in today's…

Brief by WorldPing · Original reporting by STAT